BACKGROUND:Rehabilitation brace can significantly improve the motor function of patients with post-stroke hemiplegia. OBJECTIVE:To investigate the types and biocompatibility of brace materials for post-stroke hemiplegia. METHODS: A computer-based search of Wanfang, CNKI, PubMed databases was performed for articles related to post-stroke hemiplegia and biocompatibility of brace materials published from 1999 to 2015 using the keywords of cerebral apoplexy, hemiplegia, support, material in Chinese and English, respectively. In the same field, the articles published recently or in authoritative journals were preferred. Finaly, 15 articles were enroled in result analysis. RESULTS AND CONCLUSION: Thermoplastic orthoses are mainly made of polypropylene materials, which are used for foot drop caused by post-stroke hemiplegia. Polypropylene has high strength and good toughness, and it is also safe and non-toxic. Semi-rigid planta pedis can help the lift of the toe in swing phase. Orthoses made of polymer fiber materials are characterized by ease of use, good toughness, high strength, and good air permeability, which cannot impact X-ray examination. Carbon fiber materials have light mass, high specific strength and modulus, good anti-fatigue performance, good safety performance and good designability. Clinical trials have shown that patients wearing ankle foot orthoses made of polypropylene and carbon fiber materials have improvement in walking distance and speed of climbing stairs, and these patients also feel more balanced and secure. Experimental studies on different orthotics materials can get more patient preferences, which have a great help for the design and development of orthotics materials.

Objective To discuss the effect of collaborative family nursing management mode on self-efficacy and quality of life in patients with rheumatoid arthritis ( RA ) . Methods A total of 88 cases of RA patients from July 2013 to December 2013 in our hospital were selected as the observation group, while 86 cases of RA patients from July 2012 to December 2012 in our hospital were selected as the control group, patients in control group received routine nursing, the observation group accepted the basis of conventional nursing cooperative family nursing management mode. Compared the self-efficacy and quality of life between two groups before and after the intervention by the Chronic disease self-efficacy table ( CDSES) and quality of life scale ( RAQOL) . Results Intervention before and 6 months after intervention had been evaluated, respectively, two groups of patients self-efficacy scores before intervention differences had no statistical significance (P>0. 05). After the intervention, the scores of every self-efficacy dimensions such as complete self-management, general self-efficacy, achieve the results, deal with problems in the observation group were(6. 8 ± 0. 7),(7. 4 ± 0. 9), (7.1 ±0.9) and (7.6 ±1.0), higher than these of the control group [(4.9 ±0.7),(5.2 ±0.9),(5.3 ±0.7), (5. 1 ± 0. 9)], the differences were statistically significant (t=4. 523,3. 965,3. 569,4. 102, respectively;P<0. 01). The self-efficacy of patients after the intervention had improved significantly in both two groups, compared with before. In the observation group, patients in the physiological function, psychological function, social function, healthy self-awareness ability and overall quality of life scores were (19. 9 ± 3. 1),(15. 4 ± 2. 8),(21. 9 ± 3. 2),(23. 1 ± 4. 7),(80. 3 ± 11. 6), higher than (16. 8 ± 2. 5),(13. 1 ± 2. 2),(18. 9 ± 3. 0), (20.2±3.1),(69.0±6.3) in the control group, and the differences were statistically significant (t=5.264, 4. 635,4. 265, 4. 145, 3. 958, respectively;P < 0. 01 ). Conclusions The collaborative family nursing management increases the patient′s self-efficacy, enhances the patient self-management level and the ability to adhere health behaviors, and improves the life quality of patients.

Objective:To evaluate the efficacy and safety of apatinib in combination with chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC).Methods:37 patients orally received apatinib at 250 mg/d during concurrent chemoradiotherapy until completion of radiotherapy, complete remission assessed by imaging examination, the onset of unacceptable toxicity or death. Baseline characteristics, objective response rates (ORR) and adverse events were assessed in all enrolled patients with complete baseline and safety data. Progression-free survival (PFS) and overall survival (OS) were calculated by Kaplan-Meier method. Prognostic factors were statistically identified using Cox regression models.Results:The ORR was 85%(95% CI: 72%-98%). The median PFS was 17.9 months and the 2-year OS rate was 62%(95% CI: 48%-80%). Ineffective short-term efficacy ( HR=0.035, 995% CI: 0.02-0.652, P=0.025) was an independent risk factor for poor OS. In addition, ineffective short-term efficacy ( HR=0.104, 95% CI: 0.017-0.633, P=0.014) and lymphocytopenia ( HR=17.539, 95% CI: 2.040-150.779, P=0.009) were independent risk factors for poor PFS. Common adverse events (>60%) included lymphocytopenia (76%), leukopenia (68%) and irradiation-induced mucosal injury (65%). The most common treatment-associated grade 3 adverse event was lymphopenia (49%). Conclusions:Apatinib combined with chemoradiotherapy yield significant anti-tumor activity for HNSCC with controllable toxicity. For patients with advanced HNSCC, short-term efficacy and lymphocytopenia may be potential predictors for clinical efficacy of apatinib combined with chemoradiotherapy.